Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oral Alpan

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
American Journal of Translational Research|April 12, 2019
Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase betaRenuka P Limgala, Tabitha Jennelle, Matthew Plassmeyer, et al.
Frontiers in Allergy|June 16, 2025
Enhancing allergy diagnosis: mass spectrometry as a complementary technique to the basophil activation testNicole Wheeler, Miloslav Sanda, Lanya Rasool, et al.
The Journal of Rheumatology|June 1, 2022
Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody-Positive Patients with LivedoEcem Sevim, Salma Siddique, Madhavi Latha S Chalasani, et al.
Medrxiv : the Preprint Server for Health Sciences|January 3, 2024
STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in Refractory Chronic RhinosinusitisMichael R Abidin, Oral Alpan, Matthew Plassmeyer, et al.
Annals of Internal Medicine|May 4, 2011
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trialNicola A Hanania, Oral Alpan, Daniel L Hamilos, et al.
The Journal of Investigative Dermatology|July 22, 2014
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled studySarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, et al.
The Journal of Investigative Dermatology|December 16, 2014
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudySarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, et al.
Plos One|March 20, 2015
A pilot study of omalizumab in eosinophilic esophagitisDenise Loizou, Benjamin Enav, Edina Komlodi-Pasztor, et al.
Clinical and Translational Allergy|July 18, 2022
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)Stanley J Szefler, Graham Roberts, Adalberto S Rubin, et al.
The Journal of Allergy and Clinical Immunology|September 18, 2014
Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitisMarc E Rothenberg, Ting Wen, Allison Greenberg, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
American Journal of Translational Research|April 12, 2019
Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase betaRenuka P Limgala, Tabitha Jennelle, Matthew Plassmeyer, et al.
Frontiers in Allergy|June 16, 2025
Enhancing allergy diagnosis: mass spectrometry as a complementary technique to the basophil activation testNicole Wheeler, Miloslav Sanda, Lanya Rasool, et al.
The Journal of Rheumatology|June 1, 2022
Mammalian Target of Rapamycin Pathway Assessment in Antiphospholipid Antibody-Positive Patients with LivedoEcem Sevim, Salma Siddique, Madhavi Latha S Chalasani, et al.
Medrxiv : the Preprint Server for Health Sciences|January 3, 2024
STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in Refractory Chronic RhinosinusitisMichael R Abidin, Oral Alpan, Matthew Plassmeyer, et al.
Annals of Internal Medicine|May 4, 2011
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trialNicola A Hanania, Oral Alpan, Daniel L Hamilos, et al.
The Journal of Investigative Dermatology|July 22, 2014
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled studySarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, et al.
The Journal of Investigative Dermatology|December 16, 2014
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudySarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, et al.
Plos One|March 20, 2015
A pilot study of omalizumab in eosinophilic esophagitisDenise Loizou, Benjamin Enav, Edina Komlodi-Pasztor, et al.
Clinical and Translational Allergy|July 18, 2022
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)Stanley J Szefler, Graham Roberts, Adalberto S Rubin, et al.
The Journal of Allergy and Clinical Immunology|September 18, 2014
Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitisMarc E Rothenberg, Ting Wen, Allison Greenberg, et al.
Pageof 4